Longevity Daily
The most relevant research on longevity, biohacking, and regenerative medicine — straight from the world’s best sources. No marketing filters.
Fight Aging! Newsletter, October 12th 2026
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe to the n
How much do symptomatic treatments for Alzheimer’s disease help?
Cholinesterase inhibitors have been a mainstay of Alzheimer’s treatment for decades. How much cognitive function do they preserve, and what does that mean for patients? The post How much do symptomatic treatments for Alzheimer’s disease help? appeared first on Peter Attia MD .
Arguing that Methionine Restriction is Actually Cysteine Restriction
A reduced intake of calories triggers protective responses to low nutrient availability, dramatically altering the operation of cellular metabolism. For so long as adequate levels micronutrients are still ingested, this response to calorie restriction is beneficial. The cell main
Biological age test to steer GLP-1 prescriptions
Deep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every quarter. A routine blood test is about to sit at the center of a new US telehealth service, and the pitch is that your blood knows your age better than you do
Genentech pays $100m upfront for Alector’s AL050
The Parkinson’s enzyme therapy is still heading toward the clinic, and the deal could grow by up to $1.17bn in milestone payments. Genentech has agreed to pay Alector $100 million for a Parkinson’s drug that, by Alector’s own account, is still on its way to the clinic. Alector an
Tiny Health lands $33m to read the gut for life
The Austin-based microbiome testing company raised a $33m Series B, and adults now outnumber babies in its testing volume. A company that began by testing babies’ guts now does more adult testing than pediatric. Tiny Health, based in Austin, Texas, has announced a $33 million ov
Alzinova’s Alzheimer’s vaccine heads to CTAD stage
Swedish biotech will present the Phase II ADVANCE trial design for vaccine candidate ALZ-101 at Alzheimer’s disease conference in Boston. Alzinova doesn’t have trial results to show off yet. What it has, and what it’s bringing to Boston this November, is a study design the compan
FDA talks could set the bar for a Lewy body drug
Cognition Therapeutics will meet the agency on 20 October to agree on how a Phase 3 trial of zervimesine should measure success. For some people with dementia with Lewy bodies (DLB), the earliest sign can be hallucinations, sometimes before memory and thinking visibly slip. That
EU longevity strategy gains political momentum
European Parliament conference calls for coordinated action on geroscience, preventive healthcare and healthy aging research. In a building better acquainted with fisheries quotas and the finer points of the Digital Markets Act, the biology of aging made an unusual appearance on
Jupiter Neurosciences doses first patient in Parkinson’s disease Phase 2a trial
Jupiter Neurosciences has dosed the first patient in its Phase 2a RESET trial of JOTROL in Parkinson’s disease, marking a clinical milestone. RESET is a multicenter, randomized, double-blind, placebo-controlled study expected to enroll about 30 patients randomized 1:1:1 to two do
Cerevance reports Solengepras reduced daily OFF time in Parkinson’s study
Cerevance announced positive topline results from ARISE, its randomized, double-blind, placebo-controlled Phase 3 trial of once-daily oral Solengepras as an adjunctive treatment for people with Parkinson’s disease experiencing motor fluctuations. Solengepras 150 mg met the trial’
IGFBP5 Overexpression Reduces Dental Follicle Stem Cell Senescence in the Treatment of Periodontitis
Dental follicle stem cells can be used as a basis for regenerative cell therapy in the treatment of periodontitis, the prevalent form of gum disease, and a condition that becomes more common with age. Researchers here note that IGFBP5 expression is reduced in senescent dental fol
Assessing the Burden of Somatic Mutation in Healthy Individuals versus Cancer Patients
Cancers are primarily age-related conditions for a range of reasons, such as the decline of the immune system's ability to find and destroy cancerous cells, a rising burden of senescent cells providing a more hospitable environment for cancerous growth, and the fact that the cell
Succinate Dehydrogenase as a Regulator of the Regenerative Capacity of the Heart
The tissues of the mammalian body span a broad range of regenerative capacity, from the highly regenerative liver to the minimal regenerative capabilities of the brain and the heart. We might speculate that the evolutionary road to a reduced capability of regeneration in the cent
An Aging Clock Built on Speech Analysis Data
Any sufficiently complex set of biological data that changes with age can be used as the basis for an aging clock. Well established machine learning techniques can identify patterns and find optimal correlations between algorithmic combinations of measurements taken from the data
The Gut Microbiome Worsens the Maladaptive Immune Response to Stroke
Added to the growing list of specific ways in which the gut microbiome can contribute to degenerative aging, researchers here note that indole produced by gut microbiobes provokes a chain of events that worsens the maladaptive inflammatory immune response to the damage of an isch
Exercise Slows Epigenetic Aging and Improves Cognitive Function in Cancer Survivors
Cancer survivors who underwent chemotherapy or radiotherapy in the course of putting their cancer into remission have been shown to exhibit an increased burden of senescent cells relative to healthy peers. This is thought to explain the observed reduction in life expectancy and i
#410 ‒ The biology of pregnancy: physiologic adaptation, gestational diabetes, preeclampsia, childbirth, and long-term maternal health | Kathryn Gray, M.D., Ph.D.
“[Pregnancy] It’s a cardiovascular stress test because the plasma volume expands so much. It is a metabolic stress test because there's increased insulin resistance.”‒ Katie Gray The post #410 ‒ The biology of pregnancy: physiologic adaptation, gestational diabetes, preeclampsia,
Myostatin inhibitors and the paradox of larger but weaker muscles
Drugs, new and old, that preserve lean mass, but fail to boost strength The post Myostatin inhibitors and the paradox of larger but weaker muscles appeared first on Peter Attia MD .
The end of Alzheimer’s?
A prevention strategy is in clinical trials The post The end of Alzheimer’s? appeared first on Peter Attia MD .
#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.
“The way this works is… at a very high level, making a new drug that's used by many people takes longer, is more expensive, and takes as many people as building the biggest skyscraper in the world. Think the Burj Khalifa.”‒ Lloyd Klickstein The post #409 ‒ Inside modern drug deve
Prioritizing health interventions
Separating high-impact interventions from those that matter only at the margins The post Prioritizing health interventions appeared first on Peter Attia MD .
#408 ‒ AMA #89: Thyroid health: interpreting symptoms, diagnosing and treating dysfunction, and navigating the gray zone
“The goal of this podcast, of course, is then to walk people through the physiology carefully enough that you can see both the grains of truth on each side of those schools of thought, but perhaps more importantly, what they might be missing and therefore where we can hopefully l
Can semaglutide slow aging?
A new study found that semaglutide extended median lifespan and improved several measures of aging in female mice—but the headline requires careful interpretation. The post Can semaglutide slow aging? appeared first on Peter Attia MD .
Get it weekly in your inbox
The most comprehensive weekly longevity digest. No spam. Only the best of real science.
Subscribe to newsletterComing soon. Generate your protocol with My Protocol to be the first.